Cell cycle regulatory proteins in tumor cells

Cell cycle regulation in tumor cells encompasses the collection of molecular mechanisms and proteins that govern cell division, replication, and progression through phases of the cell cycle (G1, S, G2, M). In cancer, these processes are often dysregulated by genetic or epigenetic changes, resulting in unchecked proliferation. The core machinery includes cyclins, cyclin-dependent kinases (CDKs), CDK inhibitors, checkpoint kinases, and associated regulatory factors. Inhibitors of these proteins—especially CDK4/6 inhibitors and Wee1 inhibitors—can arrest tumor cell growth and induce apoptosis, offering a selective therapeutic strategy. Many cell cycle regulators are dispensable in normal cells but crucial in tumor cells, enabling selective targeting and reduced toxicity[1][2][3][4][5]. Recent approaches include molecular degraders (such as PROTACs) to eliminate key cell cycle proteins, and combination therapies to overcome resistance and improve efficacy. In summary: "Cell cycle regulation in tumor cells" is not a precise molecular target, but an umbrella term covering multiple key proteins and complexes considered major therapeutic targets in cancer. For structured data, it is necessary to specify the individual molecule or complex of interest (e.g., Cyclin D-CDK4/6 complex, CDK2, Wee1, etc.) for more detailed annotation.

Other names

Cell cycle machinerycell cycle checkpointscell cycle proteinscell cycle regulators

Cyclin-dependent kinase inhibition (causes cell cycle arrest); Checkpoint kinase inhibition (interferes with DNA damage response); Protein degradation (PROTAC-mediated depletion of cell cycle regulators); Antagonism of mitotic regulators